Patents Issued in November 24, 2016
  • Publication number: 20160340405
    Abstract: The present invention provides methods and compositions for optimally co-expressing in a primate subject a tyrosylprotein sulfotransferase (TPST) and a lentiviral gp120-binding molecule to provide potent and long term protection against lentiviral infections.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 24, 2016
    Inventors: Matthew Gardner, Michael Farzan
  • Publication number: 20160340406
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Application
    Filed: January 21, 2015
    Publication date: November 24, 2016
    Applicants: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • Publication number: 20160340407
    Abstract: The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma, A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 24, 2016
    Applicant: Dana-Farber Camcer Institute, Inc.
    Inventors: F. Stephen Hodi, Jun Zhou, Gordon J. Freeman, Jingjing Li, Xinqi Wu
  • Publication number: 20160340408
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 24, 2016
    Inventors: Glen Eugene MIKESELL, Han Chang, Robert James Peach
  • Publication number: 20160340409
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Application
    Filed: June 9, 2016
    Publication date: November 24, 2016
    Inventor: Michal DRANITZKI-ELHALEL
  • Publication number: 20160340410
    Abstract: A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
    Type: Application
    Filed: January 20, 2015
    Publication date: November 24, 2016
    Applicant: OCTAPHARMA AG
    Inventors: Stefan Winge, Marina Dadaian, Erica Johansson, Birte Fuchs
  • Publication number: 20160340411
    Abstract: This disclosure provides for methods and compositions for the expression and secretion of heme-containing polypeptides.
    Type: Application
    Filed: September 11, 2014
    Publication date: November 24, 2016
    Inventors: Rachel Fraser, Simon Christopher Davis, Patrick O'Reilly Brown
  • Publication number: 20160340412
    Abstract: The present invention relates to a method of producing a modified protein having an increased stability and/or improved folding efficiency as compared to the unmodified protein, the method comprising (i) modifying a nucleic acid molecule encoding a protein comprising at least one immunoglobulin constant domain-like region by (a-i) replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the loop separating the C strand from the D strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp and/or replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the helix connecting the E strand with the F strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp; (a-ii) replacing the nucleotides encoding at least one amino acid not having a side chain that can form a hydrogen bond in the loop separating the C strand fr
    Type: Application
    Filed: January 7, 2015
    Publication date: November 24, 2016
    Applicants: Technische Universität München, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Johannes Buchner, Matthias Feige, Moritz Marcinowski, Janosch Hennig
  • Publication number: 20160340413
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 27, 2016
    Publication date: November 24, 2016
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Publication number: 20160340414
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 24, 2016
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Publication number: 20160340415
    Abstract: The invention provides for an antibody comprising at least one binding site that specifically binds to a LukGH complex, which antibody comprises at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Table 1, or functionally active CDR variants thereof.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 24, 2016
    Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Irina MIRKINA, Michael Benjamin BATTLES, Laura M. WALKER, Nels NIELSON, S. Jain TUSHAR
  • Publication number: 20160340416
    Abstract: For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 24, 2016
    Applicants: Ostrich Pharma KK, Immortal Spirit Limited
    Inventor: Yasuhiro TSUKAMOTO
  • Publication number: 20160340417
    Abstract: The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament.
    Type: Application
    Filed: August 8, 2016
    Publication date: November 24, 2016
    Inventors: Michael PFEIL, Josef Friedrich, Harold Victor Taylor, Karl-Heinz Eisele, Cornelia Brünn
  • Publication number: 20160340418
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 24, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Publication number: 20160340419
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 24, 2016
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Masaharu TORIKAI, Akihiko HOSOI, Tomoyo TAKEO, Masayo UENO, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU, Mineyuki MIZUGUCHI
  • Publication number: 20160340420
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 24, 2016
    Inventors: Huixiang Zhang, Charles Boring, Alok Kulshreshtha, Yuhong Zeng, Li Wan, Laman Alani
  • Publication number: 20160340421
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 24, 2016
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20160340422
    Abstract: The present invention provides a bifunctional fusion protein comprising the extracellular region of CTLA4 and an anti-IL-17 antibody, a gene encoding the protein, a vector comprising the gene, a host cell comprising the vector, and a pharmaceutical composition containing the protein.
    Type: Application
    Filed: January 28, 2015
    Publication date: November 24, 2016
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Guoqiang Chen, Jiawang Liu, Nanmeng Song, Yaping Yang, Mi Young Cha
  • Publication number: 20160340423
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.
    Type: Application
    Filed: February 26, 2016
    Publication date: November 24, 2016
    Inventor: Jeffrey T.L. Smith
  • Publication number: 20160340424
    Abstract: The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
    Type: Application
    Filed: January 22, 2015
    Publication date: November 24, 2016
    Applicants: UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florian SENNLAUB, Xavier GUILLONNEAU, Olivier LEVY, José-Alain SAHEL
  • Publication number: 20160340425
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: December 7, 2015
    Publication date: November 24, 2016
    Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
  • Publication number: 20160340426
    Abstract: The use of a modulator of the Nav 1.9 sodium channel is described for treating an inflammatory skin disease. Also described, is a pharmaceutical composition including a modulator of the Nav 1.9 sodium channel, and in vitro diagnostic methods based on the detection or quantification of Nav 1.9.
    Type: Application
    Filed: June 27, 2014
    Publication date: November 24, 2016
    Inventors: Marcel CREST, Patrick DELMAS, Aurélie LONIGRO-RAME, Nancy OSORI
  • Publication number: 20160340427
    Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Applicant: Immunwork Inc.
    Inventors: Tse-Wen CHANG, Hsing-Mao CHU, Jou-Han CHEN, Li-Yun DU
  • Publication number: 20160340428
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 24, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Publication number: 20160340429
    Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 24, 2016
    Inventors: Samuel WAKSAL, Zhenping ZHU, Yan WU, Stella MARTOMO, Zhaojing ZHONG, Dan LU
  • Publication number: 20160340430
    Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.
    Type: Application
    Filed: August 8, 2016
    Publication date: November 24, 2016
    Inventors: Atul Bedi, Rajani Ravi
  • Publication number: 20160340431
    Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 24, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine SCHOLZ
  • Publication number: 20160340432
    Abstract: Methods for achieving clinical response of Crohn's disease in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 24, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine Scholz
  • Publication number: 20160340433
    Abstract: The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts; hydroxychloroquine; an antifolate, such as methotrexate; a pynmidine synthesis inhibitor, such as leflunomide; or a sulfa drug, such as sulfasalazine. For example, the DMARD can be methotrexate, administered at a dose of mg/week or less; leflunomide, administered at a dose of 20 mg/day or less; sulfasalazine, administered at a dose of 3000 mg/day or less; or hydroxychloroquine, administered at a dose of 400 mg/day or less.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 24, 2016
    Inventor: Mark Totoritis
  • Publication number: 20160340434
    Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
    Type: Application
    Filed: February 19, 2016
    Publication date: November 24, 2016
    Applicant: Amgen Inc.
    Inventors: Kenneth Allan BRASEL, James F. SMOTHERS, Douglas Pat CERRETTI
  • Publication number: 20160340435
    Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Applicant: Immunwork Inc.
    Inventors: Tse-Wen CHANG, Hsing-Mao CHU, Wei-Ting TIAN
  • Publication number: 20160340436
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 8, 2014
    Publication date: November 24, 2016
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Publication number: 20160340437
    Abstract: This disclosure relates to methods of treating or preventing sepsis, severe sepsis, or septic shock comprising administering an effective amount of a 2B4 antibody, a CD48 variant, a CD48 antibody or specific binding agent thereof to a subject in need thereof. In certain embodiments, the subject is in need thereof because the subject is diagnosed with, exhibiting symptoms of, or at risk for sepsis.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 24, 2016
    Inventors: Mandy L. Ford, Craig Coopersmith
  • Publication number: 20160340438
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 24, 2016
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Publication number: 20160340439
    Abstract: Methods, compositions, and kits are provided for inducing an immune response in an individual (e.g., an individual having cancer). Aspects of the methods include administering an antibody composition having an allogeneic IgG antibody; and administering a treatment that activates antigen presenting cells. In some cases, the antibody composition includes polyclonal allogeneic IgG antibodies with a plurality of binding specificities. In some cases, the polyclonal antibodies are from sera pooled from 2 or more individuals. In some cases, the methods include administering an antigen presenting cell stimulatory agent. Aspects of the methods also include contacting an antigen presenting cell (dendritic cell (DC)) from an individual with a target antigen and an antibody composition having an allogeneic IgG antibody to produce a loaded APC, which can be used to induce an immune response in the individual. Aspects of the methods also include contacting a T cell of the individual with the loaded APC.
    Type: Application
    Filed: January 22, 2015
    Publication date: November 24, 2016
    Inventors: Edgar George Engleman, Yaron Carmi
  • Publication number: 20160340440
    Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 24, 2016
    Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
  • Publication number: 20160340441
    Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.
    Type: Application
    Filed: May 27, 2016
    Publication date: November 24, 2016
    Applicant: Japan Science and Technology Agency
    Inventors: Taizo UDA, Emi HIFUMI
  • Publication number: 20160340442
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Application
    Filed: January 29, 2015
    Publication date: November 24, 2016
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. KUFE, Surender KHARBANDA
  • Publication number: 20160340443
    Abstract: The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
    Type: Application
    Filed: August 9, 2016
    Publication date: November 24, 2016
    Inventors: Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20160340444
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Publication number: 20160340445
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 24, 2016
    Inventors: Julie BOUCKAERT, Sebastien GOUIN, Adeline SIVIGNON, Arlette DARFEUILLE-MICHAUD (Deceased), Rostyslav BILYY, Dimitri ALVAREZ-DORTA, Nao YAMAKAWA, Tetiana DUMYCH
  • Publication number: 20160340446
    Abstract: The purpose of the present invention is to provide a modified polymer that significantly reduces heat build-up due to the modification when the modified polymer is formed into a rubber composition, a rubber composition containing the modified polymer, and a pneumatic tire in which the rubber composition is used. The modified polymer of the present invention is a modified polymer obtained by modifying a styrene-conjugated diene copolymer (A) with a nitrone compound (B). In the modified polymer, the content of styrene units in the styrene-conjugated diene copolymer (A) is 10% by mass or greater, and the proportion of vinyl bonds among all the double bonds contained in the styrene-conjugated diene copolymer (A) is 5 mol % or greater.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 24, 2016
    Applicant: THE YOKOHAM RUBBER CO., LTD.
    Inventors: Ryota TAKAHASHI, Manabu KATO, Takahiro OKAMATSU, Yoshiaki KIRINO
  • Publication number: 20160340447
    Abstract: A method for preparing a coupled polymer, the method comprising the steps of (i) polymerizing monomers to form a reactive polymer, and (ii) reacting the reactive polymer with a glycidic ester.
    Type: Application
    Filed: August 1, 2016
    Publication date: November 24, 2016
    Applicant: BRIDGESTONE CORPORATION
    Inventor: Steven Luo
  • Publication number: 20160340448
    Abstract: Provided is a fluorine-containing macroinitiator, particularly a fluorine-containing macroinitiator that enables production of a fluorine-containing block copolymer containing a non-fluorine vinyl-based monomer having a long side chain. The fluorine-containing macroinitiator includes a polymer represented by the following formula (1) and having a number-average molecular weight of 3,000 to 100,000. In the following formula (1), R2, R3 and R4 are each a specific group, and Q is a polymer segment composed of a structural unit represented by the following formula (2). In the following formula (2), R1 is a hydrogen atom or a methyl group, Rf is a fluoroalkyl group having a specific structure, and k is an appropriate integer that is not 0.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 24, 2016
    Inventors: Satoru Saito, Katsuyuki Sato, Takehiro Sonoi
  • Publication number: 20160340449
    Abstract: Disentangled high or ultrahigh molecular weight polyethylene ((U)HMWPE) being produced with a Ziegler-Natta catalyst, characterized by (i) a factor for the normalized elastic modulus G?0/G?P of less than 0.95 determined in a dynamic time sweep measurement at 180° C. with constant strain of 0.5% at fixed frequency of 10 rad/s for at least 3600 s, whereby G?0 is the elastic shear modulus measured at t0 directly after melting the sample and G?p is the maximum plateau modulus.
    Type: Application
    Filed: February 6, 2015
    Publication date: November 24, 2016
    Inventors: Thomas Hjertberg, Alexandra Romina Albunia, Yi Liu, Qizheng Dou
  • Publication number: 20160340450
    Abstract: Catalyst compositions containing activator-supports and half-metallocene titanium phosphinimide complexes or half-metallocene titanium iminoimidazolidide complexes are disclosed. These catalyst compositions can be used to produce olefin polymers having relatively broad molecular weight distributions and low levels of long chain branching.
    Type: Application
    Filed: August 2, 2016
    Publication date: November 24, 2016
    Inventors: Carlos A. Cruz, Jared L. Barr, Jeremy M. Praetorius
  • Publication number: 20160340451
    Abstract: The present invention relates to a metallocene compound having novel structure which can provide various selectivity and activity to polyolefin copolymers, a preparation method thereof, and a preparation method of polyolefin using the metallocene compound.
    Type: Application
    Filed: October 8, 2015
    Publication date: November 24, 2016
    Applicant: LG CHEM, Ltd.
    Inventors: Hee Kwang PARK, Hye Kyung LEE, Byubg Seok KIM, Jae Youp CHEONG, Kyung Seop NOH, Ra Yun CHOI, Sang Hoon LEE, Sang Jin JEON
  • Publication number: 20160340452
    Abstract: The present invention relates to a method of preparing a vinyl chloride polymer having good thermal stability due to the restraint of dehydrochlorination by heat or ultraviolet rays, and a vinyl chloride polymer prepared thereby. In the preparation method, a modifier is introduced at the end of a polymerization process to impart the vinyl chloride polymer with high thermal stability without inducing modification. Therefore, the generation of dehydrochlorination due to heat or ultraviolet rays may be markedly restrained, thermal stability may be improved, and discoloration or the modification of physical properties may be prevented in the vinyl chloride polymer thus prepared.
    Type: Application
    Filed: September 14, 2015
    Publication date: November 24, 2016
    Inventors: Kyung Seog YOUK, Kyung Hyun KIM, Hyun Min LEE, Yong Jin KIM, Heung Kwon BAE, Jung Rae LEE
  • Publication number: 20160340453
    Abstract: The instant invention provides a polyolefin composition, a catalyst composition, and a method of producing the same. The method for polymerizing one or more polyolefins according to the present invention comprises the steps of: (1) selecting a first olefin monomer and optionally one or more alpha-olefin comonomers; (2) selecting one or more catalyst systems comprising one or more procatalysts comprising a first metal selected from the group consisting of Ti, V, Hf, Zr, and combinations or mixture two or more thereof, one or more cocatalysts comprising Al, and one or more self-limiting agents (SLA) selected from the group consisting of polyether, polyester, and combinations or mixtures thereof; wherein the ratio of said SLA to said first metal (SLA:first metal) is from 0.
    Type: Application
    Filed: October 30, 2014
    Publication date: November 24, 2016
    Applicant: Dow Global Technologies LLC
    Inventors: Linfeng Chen, Stephanie M. Whited, Robert J. Jorgensen
  • Publication number: 20160340454
    Abstract: A process for controlling the placement of alpha olefins within an ethylene copolymer. The process involves polymerizing ethylene and an alpha olefin in the gas phase while changing the breadth of control over the molar ratio of ethylene to comonomer and/or hydrogen which is being fed to a polymerization reactor. At tighter control breadths, the alpha olefin may be incorporated mainly in the higher molecular weight portions of the ethylene copolymer.
    Type: Application
    Filed: May 9, 2016
    Publication date: November 24, 2016
    Applicant: NOVA Chemicals (International) S.A.
    Inventors: Bradley Wade Funk, Peter Phung Minh Hoang